ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-κB/STAT3/GPX4 axis

Zhong, Xing; Zhang, Weiwei; Zhang, Weiming; Yu, Nasha; Li, Wuping; Song, Xiangxiang
CANCER BIOLOGY & THERAPY2024-12-31DOI: 10.1080/15384047.2024.2403197
1阅读
引用收藏
分享

摘要

Drug resistance is a critical impediment to efficient therapy of diffuse large B-cell lymphoma (DLBCL) patients. Recent studies have highlighted the association between ferroptosis and drug resistance that has been reported. Fatty acid synthase (FASN) is always related to a poor prognosis. In this study, we investigate the impact of FASN on drug resistance in DLBCL and explore its potential modulation of ferroptosis mechanisms. The clinical correlation of FASN mRNA expression was first analyzed to confirm the role of FASN on drug resistance in DLBCL based on the TCGA database. Next, the impact of FASN on ferroptosis was investigated in vitro and in vivo. Furthermore, a combination of RNA-seq, western blot, luciferase reporter, and ChIP experiments was employed to elucidate the underlying mechanism. The prognosis for patients with DLBCL was worse when FASN was highly expressed, particularly in those undergoing chemotherapy for Adriamycin (ADM). FASN promoted tumor growth and resistance of DLBCL to ADM, both in vitro and in vivo. It is noteworthy that this effect was achieved by inhibiting ferroptosis, since Fer-1 (a ferroptosis inhibitor) treatment significantly recovered the effects of silencing FASN on inhibiting ferroptosis, while Erastin (a ferroptosis inducer) treatment attenuated the impact of overexpressing FASN. Mechanistically, FASN activated NF-κB/STAT3 signaling pathway through phosphorylating the upstream IKKα and IκBα, and the activated STAT3 promoted GPX4 expression by directly binding to GPX4 promoter. FASN inhibits ferroptosis in DLBCL via NF-κB/STAT3/GPX4 signaling pathway, indicating its critical role in mediating ADM resistance of DLBCL.

学科与关键词

关键词
DLBCLFASNNf-κB/STAT3/GPX4 axisdrug resistanceferroptosis
相关
加载中…
  • High-dose radiation-resistant lung cancer cells stored many functional lipid drops through JAK2/p-STAT3/FASN pathway
    Yang, Ting; Qiao, Simiao; Zhu, Xiaoxia*Journal of Cancer Research and Clinical Oncology, 2023, 149(15): 14169-14183.
  • Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma
    Pi, Manfei; Kuang, Huixian; Yue, Chunyan; Yang, Qixuan; Wu, Anqin; Li, Yuhua; Assaraf, Yehuda G.; Yang, Dong-Hua*; Wu, Shaojie*DRUG RESISTANCE UPDATES, 2022, 61: 100822.被引 24
  • Proton pump inhibitors suppress DNA damage repair and sensitize treatment resistance in breast cancer by targeting fatty acid synthase
    Wang, Chao J.; Li, Deren; Danielson, Jacob A.; Zhang, Evan H.; Dong, Zizheng; Miller, Kathy D.; Li, Lang; Zhang, Jian-Ting*; Liu, Jing-Yuan*Cancer Letters, 2021, 509: 1-12.
查看全部 →

发表信息

论文状态
公开发表
期刊
CANCER BIOLOGY & THERAPY
发表日期
2024-12-31
卷期
第 25 卷, 第 1 期
页码
2403197
DOI
10.1080/15384047.2024.2403197
语言
ENGLISH
成果收录
PUBMED

作者

  • Z

    Zhong, Xing (第一作者)

  • Z

    Zhang, Weiwei

查看全部 6 位作者收起作者
  • Z

    Zhang, Weiming

  • Y

    Yu, Nasha

  • L

    Li, Wuping

  • S

    Song, Xiangxiang

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417